Telix Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Telix Pharmaceuticals' es Chris Behrenbruch , nombrado en Jul 2023, tiene una permanencia de menos de un año. compensación anual total es A$1.02M, compuesta por 49% salario y 51% primas, incluidas acciones y opciones de la empresa. posee directamente un 7.03% de las acciones de la empresa, por valor de A$327.52M. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 6.6 años, respectivamente.

Información clave

Chris Behrenbruch

Chief Executive Officer (CEO)

AU$1.0m

Compensación total

Porcentaje del salario del CEO	49.0%
Permanencia del CEO	less than a year
Participación del CEO	7.0%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	6.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Behrenbruch en comparación con los beneficios de Telix Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	AU$1m	AU$499k	AU$5m
Sep 30 2023	n/a	n/a	-AU$21m
Jun 30 2023	n/a	n/a	-AU$48m
Mar 31 2023	n/a	n/a	-AU$76m
Dec 31 2022	AU$865k	AU$422k	-AU$104m
Sep 30 2022	n/a	n/a	-AU$111m
Jun 30 2022	n/a	n/a	-AU$119m
Mar 31 2022	n/a	n/a	-AU$100m
Dec 31 2021	AU$620k	AU$374k	-AU$81m
Sep 30 2021	n/a	n/a	-AU$70m
Jun 30 2021	n/a	n/a	-AU$59m
Mar 31 2021	n/a	n/a	-AU$52m
Dec 31 2020	AU$421k	AU$295k	-AU$45m
Sep 30 2020	n/a	n/a	-AU$40m
Jun 30 2020	n/a	n/a	-AU$36m
Mar 31 2020	n/a	n/a	-AU$32m
Dec 31 2019	AU$460k	AU$317k	-AU$28m
Sep 30 2019	n/a	n/a	-AU$23m
Jun 30 2019	n/a	n/a	-AU$19m
Mar 31 2019	n/a	n/a	-AU$16m
Dec 31 2018	AU$380k	AU$280k	-AU$14m
Sep 30 2018	n/a	n/a	-AU$12m
Jun 30 2018	n/a	n/a	-AU$10m
Mar 31 2018	n/a	n/a	-AU$8m
Dec 31 2017	AU$303k	AU$211k	-AU$6m

Compensación vs. Mercado: La compensación total de Chris($USD656.86K) está por debajo de la media de empresas de tamaño similar en el mercado Australian ($USD2.10M).

Compensación vs. Ingresos: La compensación de Chris ha sido consistente con los resultados de la empresa en el último año.

CEO

Chris Behrenbruch (47 yo)

less than a year

Permanencia

AU$1,018,461

Compensación

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christian Behrenbruch	Co-Founder	less than a year	AU$1.02m	7.03% A$ 340.8m
Darren Smith	Group Chief Financial Officer	1.8yrs	AU$713.90k	0.0020% A$ 95.5k
Andreas Kluge	Chief Medical Advisor & Non-Executive Director	no data	AU$43.00k	6.86% A$ 332.6m
Richard Valeix	Group Chief Commercial Officer	3yrs	AU$902.90k	0.038% A$ 1.8m
Darren Patti	Group Chief Operating Officer	less than a year	sin datos	sin datos
Michael Wheatcroft	Chief Scientist	3yrs	AU$167.76k	sin datos
Craig Ulrick	Chief Information Officer	1.3yrs	sin datos	sin datos
Kyahn Williamson	Senior Vice President of Corporate Communications & Investor Relations	2.8yrs	sin datos	sin datos
Melanie Farris	Senior VP of Global Governance	1.4yrs	sin datos	sin datos
Lena Moran-Adams	Group General Counsel	1.7yrs	sin datos	sin datos
Thomas Fromm	Vice President of Sales	no data	sin datos	sin datos
Meredith Crowe	Senior Vice President of Global People & Culture	1.7yrs	sin datos	sin datos

1.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de TLX no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christian Behrenbruch	Co-Founder	7.3yrs	AU$1.02m	7.03% A$ 340.8m
Andreas Kluge	Chief Medical Advisor & Non-Executive Director	7.3yrs	AU$43.00k	6.86% A$ 332.6m
Harry McCann	Independent Non-Executive Chairman	6.7yrs	AU$188.28k	0.35% A$ 16.9m
Chaitanya Divgi	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Rodney Hicks	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Neil Bander	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Mark Nelson	Independent Non-Executive Director	6.7yrs	AU$103.30k	1.1% A$ 53.2m
Jann Skinner	Independent Non-Executive Director	5.9yrs	AU$111.56k	0.18% A$ 8.7m
Jean-François Chatal	Member of the Scientific Advisory Board	no data	sin datos	0.54% A$ 26.4m
Jason Lewis	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Klaus Kopka	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Samuel Samnick	Member of the Scientific Advisory Board	no data	sin datos	sin datos

6.7yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de TLX se considera experimentada (6.6 años de antigüedad promedio).

Telix Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Co-Founder exercised options to buy AU$1.7m worth of stock.

Telix Pharmaceuticals Limited Announces Executive Changes

Insider recently bought AU$343k worth of stock

Insider recently bought AU$73k worth of stock

Telix Pharmaceuticals Limited Announces Leadership Changes

Recent updates

Consensus EPS estimates increase by 30%

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

Now 20% overvalued after recent price rise

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent

Consensus EPS estimates fall by 19%

Price target increased by 7.5% to AU$14.47

Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million.

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.

Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022)

Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024

Co-Founder exercised options to buy AU$1.7m worth of stock.

Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited Announces Executive Changes

Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

Price target increased by 8.0% to AU$13.37

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million.

Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591

Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies

Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023

New minor risk - Shareholder dilution

Forecast to breakeven in 2023

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.23 loss in 1H 2022)

Forecast to breakeven in 2023

Forecast breakeven date moved forward to 2023

Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023

Forecast to breakeven in 2023

Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023

Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI

Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million.

Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion

Price target increased by 7.5% to AU$11.82

Price target increased by 8.8% to AU$10.54

Price target increased by 8.8% to AU$10.54

Insider recently bought AU$343k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial

Consensus EPS estimates fall by 14%, revenue upgraded

Forecast breakeven date pushed back to 2024

Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023

Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Insider recently bought AU$73k worth of stock

Telix Pharmaceuticals Limited Announces Leadership Changes

Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection

Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

Non-Executive Director exercised options to buy AU$3.5m worth of stock.

Insufficient new directors

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center.

Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints

Non-Executive Director exercised options to buy AU$3.4m worth of stock.

Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Forecast breakeven date moved forward to 2023

Consensus revenue estimates increase by 19%

Telix Pharmaceuticals Limited Presents Preliminary Data on TLX250-CDx Indication Expansion at EANM

Telix Pharmaceuticals Limited to Report Q3, 2022 Results on Oct 20, 2022

Telix Pharmaceuticals Limited Announces Health Canada Approves Illuccix for Prostate Cancer Imaging

Telix Pharmaceuticals Limited Announces First Patient in New Zealand Dosed with Illuccix

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

Telix Pharmaceuticals Limited and GenesisCare announce First Patient Enroll in ProstACT TARGET Study

Telix Pharmaceuticals Limited Reports the Final Results from the IPAX-1 Ph I/II Study of TLX101 Therapy Iodo-Phenylalanine

Telix Pharmaceuticals Limited and Atonco S.A.S. Announce That the Final Patient Dosed in A Phase I Study of TLX250-CDx in Patients with Non-Muscle Invasive Bladder Cancer

Consensus forecasts updated

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind